Kangliming Bio

Guangzhou Kangliming Biotechnology Co., Ltd. is a high-tech biotechnology company founded by an outstanding team of scientists. The company was established in January 2015, focusing on the R&D, production, and sales of tumor early detection products such as the Chang'an Heart colorectal cancer fecal gene detection kit and related automated detection equipment, as well as providing corresponding detection services. Third-party medical testing laboratories have been established in Guangzhou, Tianjin, Wuhan, Jinan, etc., with a total area exceeding 18,000 square meters.
The company possesses internationally cutting-edge scientific research capabilities and numerous independent intellectual property rights, and will continue to strengthen these in the future while transforming achievements into productivity. In addition to the Chang'an Heart colorectal cancer fecal gene detection product, the company is also developing non-invasive detection products and point-of-care testing devices for lung cancer, bladder cancer, cervical cancer, liver cancer, and other tumors, and has achieved encouraging preliminary results.
Adhering to the lofty ideal of "Human Health, My Mission," we strive to make breakthroughs and progress in the early diagnosis and treatment of chronic diseases, especially tumors, and prognosis monitoring, continuously benefiting the people.
Our corporate spirit is "Integrity, Innovation, Excellence, and Responsibility," and our corporate vision is "Be a Leading Molecular Diagnostic Company"!
On January 12, 2015, Kangliming Bio was established.
In July 2015, angel round financing of RMB 20 million was completed.
In June 2016, Pre-A round financing of RMB 15 million was completed.
In June 2016, fecal gene detection technology was first included in the U.S. colorectal cancer screening guidelines.
Recognized as one of China's Top 100 Innovative Growth Enterprises of 2016.
In March 2017, Chang'an Heart® entered the national medical device special approval channel.
In June 2017, A round financing of RMB 61 million was completed.
In February 2018, Dr. Zou Hongzhi was honored as a "National Major Talent Project Selectee."
On November 20, 2018, Chang'an Heart® was approved for market by the National Medical Products Administration.
On November 28, 2018, recognized as a national high-tech enterprise.
In April 2019, B round financing of RMB 300 million was completed.
Passed ISO 13485:2016 quality system certification.
In February 2020, Chang'an Heart® was approved for European listing (CE).
In March 2020, acquired Haozhi Bio company.
In March 2020, recognized as Guangdong Provincial Engineering Technology Research Center.
In September 2020, C round financing of RMB 600 million was completed.
In December 2020, launched the HelixPOC fully automated microfluidic PCR all-in-one machine.
In October 2021, D round financing of RMB 560 million was completed.
In January 2022, groundbreaking for the Guangzhou headquarters base.
Comprehensive welfare benefits:
[Compensation System] Provides employees with competitive compensation, with 1-2 salary adjustment opportunities per year.
[Working Hours] Five-day, eight-hour work system, weekends off; working hours: 8:30-17:30.
[Social Insurance and Housing Fund] Purchase upon onboarding: endowment insurance, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance, and housing provident fund.
[Paid Leave] Enjoy no less than 5 days of paid annual leave upon onboarding, plus statutory holidays, sick leave, marriage leave, maternity/paternity leave, work-related injury leave, bereavement leave, etc.
[Office Environment] Modern office environment with spacious and bright floor-to-ceiling windows filling every inch with sunlight and vitality.
[Other Benefits] Free employee cafeteria, gym, annual free travel, employee pricing for company products, internal and external training and development opportunities.
Company address: No. 10 Fenghuang Fifth Road, Huangpu District, Guangzhou
Nearby subway/bus stops:
①Exit C of Xin'an Station on Line 14;
②266/343 road - Knowledge City North Resettlement Area (Fenghuang Fifth Road) stop;
③343A road - Fenghuang Third Cross Road South stop;